Prospects for early investigational therapies for sickle cell disease

Bibliography

• Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364(9442):1343-60
   PubMed Web of Science ®Google Scholar
• Piel FB, Tatem AJ, Huang Z, et al. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health 2014;2(2):e80-9
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332(20):1317-22
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol 2011;18(3):158-65
   PubMed Web of Science ®Google Scholar
• Kassim AA, DeBaun MR. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Expert Opin Pharmacother 2014;15(3):325-36
   PubMed Web of Science ®Google Scholar
• Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120(22):4285-91
   PubMed Web of Science ®Google Scholar
• Kutlar A, Swerdlow PS, Meiler SE, et al. Pomalidomide in sickle cell disease: Phase I study of a novel anti-switching agent. Blood 2013;122:abstract 777
   Google Scholar
• dos Santos JL, Lanaro C, Lima LM, et al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. J Med Chem 2011;54(16):5811-19
   PubMed Web of Science ®Google Scholar
• Fard AD, Hosseini SA, Shahjahani M, et al. Evaluation of novel fetal hemoglobin inducer drugs in treatment of beta-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res 2013;7(3):47-54
   PubMedGoogle Scholar
• Safo MK, Kato GJ. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am 2014;28(2):217-31
   PubMed Web of Science ®Google Scholar
• Niihara Y, Koh HA, Tran L, et al. A phase III study of L-glutamine therapy for Sickle cell anemia and sickle ß0-thalassemia. Blood (ASH) 2014;124(21):abstract:86
   Google Scholar
• Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a Phase III randomized, placebo-controlled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011;153(1):92-104
   PubMed Web of Science ®Google Scholar
• Chang J, Patton JT, Sarkar A, et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010;116(10):1779-86
   PubMed Web of Science ®Google Scholar
• Wun T, Styles L, DeCastro L, et al. Phase I study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One 2014;9(7):e101301
   PubMed Web of Science ®Google Scholar
• Wun T, Telen MJ, Krishnamurti L, et al. Pan-selectin antagonist rivipansel (GMI-1070) reduces soluble E-selectin levels while improving clinical outcomes in SCD vaso-occlusive crisis. Blood (ASH) 2014;124:abstract:2704
   Google Scholar
• Okpala I. Investigational selectin-targeted therapy of sickle cell disease. Expert Opin Investig Drugs 2015;24(2):229-38
   PubMed Web of Science ®Google Scholar
• Manwani DM, Chen C, Carullo V, et al. Vaso-occlusion-promoting neutrophil mac-1 integrin activation in human sickle cell crises is stabilized by a single dose of intravenous gammaglobulin. Blood (ASH) 2014;124:abstract:4089
   Google Scholar
• Cheung AT, Chan MS, Ramanujam S, et al. Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study. J Investig Med 2004;52(6):402-6
   PubMed Web of Science ®Google Scholar
• Ballas SK, Files B, Luchtman-Jones L, et al. Safety of purified poloxamer 188 in sickle cell disease: Phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 2004;28(2):85-102
   PubMed Web of Science ®Google Scholar
• Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol 2011;153(5):655-63
   PubMed Web of Science ®Google Scholar
• Field JJ, Ataga KI, Majerus EM, et al. A Phase I single ascending dose study of NKTT120 in stable adult sickle cell patients. Blood 2013;122(21):977
   Google Scholar
• Field JJ, Nathan DG, Linden J. The role of adenosine signaling in sickle cell therapeutics. Hematol Oncol Clin North Am 2014;28(2):287-99
   PubMed Web of Science ®Google Scholar
• Solovey A, Somani A, Chen CS, et al. Interference with TNF alpha using long-term etanercept in S+S-Antilles sickle transgenic mice ameliorates abnormal endothelial activation, vasoocclusion, and pulmonary hypertension including its pulmonary arterial wall remodeling. Blood 2013;122(21):728
   Google Scholar
• Howard J, Thein SL, Galacteros F, et al. Safety and tolerability of MP4CO: a dose escalation study in stable patients with sickle cell disease. Blood 2013;122(21):2205
   PubMedGoogle Scholar
• Desai PC, Brittain JE, Jones SK, et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res 2013;132(3):341-5
   PubMed Web of Science ®Google Scholar
• Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter Phase II study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013;6:17
   PubMed Web of Science ®Google Scholar
• Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014;123(3):377-90
   PubMed Web of Science ®Google Scholar
• Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest 2013;123(11):4809-20
   PubMed Web of Science ®Google Scholar
• Hanson MS, Xu H, Flewelen TC, et al. A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia. Am J Physiol Heart Circ Physiol 2013;304(2):H328-36
   Google Scholar
• Olsson MG, Allhorn M, Bulow L, et al. Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for alpha(1)-microglobulin. Antioxid Redox Signal 2012;17(5):813-46
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011;305(9):893-902
   PubMed Web of Science ®Google Scholar
• Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013;98(9):1375-82
   PubMed Web of Science ®Google Scholar
• Almeida CB, Scheiermann C, Jang JE, et al. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 2012;120(14):2879-88
   PubMed Web of Science ®Google Scholar
• De Falco S. Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med 2014;29(1):1-11
   PubMed Web of Science ®Google Scholar
• Iwase T, Fu J, Yoshida T, et al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J Control Release 2013;172(3):625-33
   PubMed Web of Science ®Google Scholar
• Casini G, Dal Monte M, Fornaciari I, et al. The beta-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res 2014;42:103-29
   PubMed Web of Science ®Google Scholar
• Impellizzeri D, Esposito E, Attley J, et al. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). Pharmacol Res 2014;81:91-102
   PubMed Web of Science ®Google Scholar
• Maguire JJ, Davenport AP. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol 2014;171(24):5555-72
   PubMed Web of Science ®Google Scholar
• Yang JJ, Tao H, Huang C, et al. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis. Food Chem Toxicol 2013;59:421-7
   PubMed Web of Science ®Google Scholar
• Nakagawa A, Lui FE, Wassaf D, et al. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces ss erythrocyte sickling. ACS Chem Biol 2014;9(10):2318-25
   PubMed Web of Science ®Google Scholar